Inovio Pharmaceuticals Inc (NASDAQ:INO) announced that its Chief Executive Officer, Dr. J. Joseph Kim, has been selected by The Aspen Institute to join its Health Innovators Fellowship. Dr. Kim, who co-founded Inovio, will work with a group of 20 healthcare leaders challenged to generate new solutions to improve healthcare treatments, access and delivery. He also joins 2,000 other Aspen Fellows from 48 countries who comprise the Aspen Global Leadership Network.
Aspen chose Dr. Kim for his leadership in advancing a new type of medicine, DNA-based immunotherapies, that may prevent and treat a broad array of cancers and challenging infectious diseases, and for his entrepreneurial spirit guiding a two-person start-up through early-stage trials into a publically traded product development company, Inovio Pharmaceuticals Inc.
The Fellowship is designed for proven, highly successful entrepreneurs and innovators in the health care field who have reached a point in their lives and careers when they are ready to use their skills and experiences to “paint on a broader canvas.” The Fellowship offers leaders a unique opportunity to reflect on how they can have an even greater positive impact on health care, and to connect with and learn from a diverse group of peers with whom they would not ordinarily interact.
“Our goal for the Health Innovators Fellowship to is to bring together a diverse group of leaders to explore how they can harness their creativity, experience and energy to solve our most pressing health care challenges,” saidRima Cohen, managing director of the Health Innovators Fellowship. “As a pioneer in developing new immunotherapies and vaccines for cancer and infectious diseases, Dr. Kim’s perspective will be invaluable to our inaugural class.”
Dr. J. Joseph Kim, President and CEO, said, “I am honored to be selected by The Aspen Institute to join the inaugural class of Health Fellows. I look forward to working with these accomplished innovators as we develop ‘big ideas’ to improve health for everyone.”
The Aspen Global Leadership Network
Health Innovators Fellows will join more than 2,000 other Fellows from 48 countries to become members of the Aspen Global Leadership Network (AGLN). The AGLN is composed of accomplished leaders who have participated in similar Aspen Institute leadership initiatives in the United States, Africa, Central America, China, India, and theMiddle East – all designed to help accomplished leaders – mostly business leaders – move from “success to significance.”
The Aspen Institute is an educational and policy studies organization based in Washington, DC. Its mission is to foster leadership based on enduring values and to provide a nonpartisan venue for dealing with critical issues. The Institute has campuses in Aspen, Colorado, and on the Wye River on Maryland’s Eastern Shore. It also maintains offices in New York City and has an international network of partners. (Original Source)
Shares of Inovio Pharmaceuticals closed last Friday at $7.46. INO has a 1-year high of $13.04 and a 1-year low of $6.33. The stock’s 50-day moving average is $8.41 and its 200-day moving average is $8.47.
On the ratings front, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on INO, with a price target of $20, in a report issued on May 11. The current price target represents a potential upside of 168.1% from where the stock is currently trading. According to TipRanks.com, Aschoff has a total average return of 12.8%, a 56.7% success rate, and is ranked #139 out of 3694 analysts.
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.